Aramchol, a novel partial inhibitor of SCD1, has shown promise as a treatment for nonalcoholic steatohepatitis (NASH) and was not linked to serious adverse effects in a phase 2b clinical study, unlike other SCD1 inhibitors [43]. The gene discussed is SCD; the disease is metabolic dysfunction-associated steatohepatitis.